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Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy for patients with
myelodysplastic syndrome (MDS). Donor T cells are critical for the graft-versus-tumor effect but carry the risk
of graft-versus-host disease (GVHD). CD34 selection with immunomagnetic beads has been an effective
method of depleting alloreactive donor T cells from the peripheral blood graft and has been shown to result in
signiﬁcant reduction in acute and chronic GVHD. We analyzed the outcomes of 102 adults (median age,
57.6 years) with advanced MDS who received a CD34-selected allo-HSCT between January 1997 and April
2012 at Memorial Sloan Kettering Cancer Center. The cumulative incidences of grades II to IV acute GVHD
were 9.8% at day 100 (95% conﬁdence interval [CI], 5.0% to 16.5%) and 15.7% at day 180 (95% CI, 9.4% to 23.4%).
The cumulative incidence of chronic GVHD at 1 year was 3.9% (95% CI, 1.3% to 9.0%). The cumulative in-
cidences of relapse were 11.8% at 1 year (95% CI, 6.4% to 18.9%) and 15.7% at 2 years (95% CI, 9.4% to 23.4%).
Forty-eight patients were alive with a median follow-up of 71.7 months. Rates of overall survival (OS) were
56.9% at 2 years (95% CI, 48% to 67.3%) and 49.3% at 5 years (95% CI, 40.4% to 60.2%). Rates of relapse-free
survival (RFS) were 52.0% at 2 years (95% CI, 41.9% to 61.1%) and 47.6% at 5 years (95% CI, 37.5% to 56.9%).
The cumulative incidences of nonrelapse mortality were 7.8% at day 100 (95% CI, 3.7% to 14.1%), 22.5% at
1 year (95% CI, 15.0% to 31.1%), and 33.4% at 5 years (95% CI, 24.2% to 42.6%) post-transplant. The incidence of
chronic GVHD/RFS overlapped with RFS. These ﬁndings demonstrate that ex vivo T celledepleted allo-HSCT
by CD34 selection offers long-term OS and RFS with low incidences of acute and chronic GVHD and without
an increased risk of relapse.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Over the past few years, there have been major advances
in understanding the biology of myelodysplastic syndrome
(MDS), particularly regarding the role of molecular muta-
tions in predicting outcomes [1-6]. Despite these excitingedgments on page 2113.
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ty for Blood and Marrow Transplantation.ﬁndings, there have been few new treatment options for
patients with MDS. Hypomethylating agents, 5-azacytidine
and 2’-deoxy-5-azacytidine are US Food and Drug Admin-
istrationeapproved drugs for the treatment of MDS with
overall response rates of 30% to 60% [7,8]. However, these are
not curative treatments; therefore, allogeneic hematopoietic
stem cell transplantation (allo-HSCT) remains the only
curative treatment available for patients with MDS [9,10].
Acute and chronic graft-versus-host disease (GVHD)
remains a signiﬁcant post-transplant complication, with
Table 1
Patients Characteristics
Variable Value
No. of patients 102
Male sex 53 (52.0%)
Median patient age, yr (range) 57.6 (21.9-73.0)
20-49 24 (23.5%)
50-65 61 (59.8%)
>65 17 (16.7%)
Etiology
De novo 82 (80.4%)
Therapy related 15 (14.7%)
Postaplastic anemia/MPD 3/2 (4.9%)
Disease status at diagnosis by WHO criteria
RA/RCMD 27 (26.5%)
RAEB-1 31 (30.4%)
RAEB-2 44 (43.1%)
IPSS-R at diagnosis
Very low 5 (4.9%)
Low 13 (12.7%)
Intermediate 21 (20.6%)
High 31 (30.4%)
Very high 26 (25.5%)
Missing data 6 (5.9%)
Disease status at transplant by WHO criteria
CR 36 (35.3%)
RA/RCMD 46 (45.1%)
RAEB-1 16 (15.7%)
RAEB-2 4 (3.9%)
IPSS-R at time of transplant
Very low 9 (8.8%)
Low 37 (36.3%)
Intermediate 28 (27.5%)
High 18 (17.6%)
Very high 8 (7.8%)
Missing data 2 (2.0%)
Time from diagnosis to transplant
<6 mo 25 (24.5%)
6-12 mo 34 (33.3%)
12-24 mo 20 (19.6%)
>24 mo 23 (22.5%)
HCT-CI
0 18 (17.6%)
1-2 26 (25.5%)
3 57 (55.0%)
Missing data 1 (1.0%)
MPD indicates myeloproliferative disorder; WHO, World Health Organiza-
tion; CR, complete response.
Table 2
Transplant Characteristics
Variable Value
Conditioning regimen
High-dose HFTBI (1375-1500 cGy) containing regimens 15 (14.7%)
HFTBI, thiotepa (10 mg/kg), cytoxan (120 mg/kg) 9
HFTBI, thiotepa (10 mg/kg), ﬂudarabine (125 mg/m2) 6
Chemotherapy-based regimens 87 (85.3%)
Busulfan (8-9.6 mg/kg), melphalan (140 mg/m2),
ﬂudarabine (125 mg/m2)
86
Busulfan (12.8 mg/kg), ﬂudarabine (150 mg/m2) 1
Donor type
Related
HLA match 37 (36.3%)
HLA mismatch 2 (2.0%)
Unrelated
HLA match 38 (37.3%)
HLA mismatch 25 (24.5%)
CD34 selection method
Clinimacs 36 (35%)
Isolex 66 (65%)
HFTBI indicates hyperfractionated total body irradiation.
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most effective method to prevent GVHD is depletion of the
alloreactive T lymphocytes from the allograft [13]. The efﬁ-
cacy of ex vivo CD34 selection strategies in reducing the risk
of acute and chronic GVHD without higher relapse rates
has been reported in previous publications [14-17]. These
ﬁndings were conﬁrmed in a prospective multicenter trial
sponsored by the Bone Marrow Transplant Clinical Trial
Network in patients with acute myeloid leukemia (AML) in
complete hematologic remission [13].
We previously reported the outcomes of 49 patients who
underwent T celledepleted (TCD) allo-HSCT for advanced
MDS (refractory anemia with excess blasts [RAEB]-1, RAEB-2,
and AML evolved from MDS) from matched related donors
[15]. In that report we showed that TCD allo-HSCT results in
favorable outcomes with a low incidence of GVHD and
relapse rates comparable with unmodiﬁed allo-HSCT, pro-
vided the blast count is reduced before transplant. Here we
report the outcomes of 102 patients who received a TCD allo-
HSCT from matched and mismatched related and unrelated
donors.
METHODS
Patients
Between January 1997 and April 2012, 102 adults with advanced MDS
underwent TCD allo-HSCT at Memorial Sloan Kettering Cancer Center.
Eligibility criteria for transplantation included a diagnosis of advanced MDS
(RAEB-1, RAEB-2) and AML post-MDS (evolved from a well-established
diagnosis of MDS or clearly documented cytopenia for at least 6 months
before diagnosis of AML), age < 75, absence of active infection, and lack of
coexisting cardiac, pulmonary, hepatic, or renal dysfunction that preclude
administration of the cytoreductive regimen.
HLA typing was performed using high-resolution DNA sequence-
speciﬁc oligonucleotide typing for HLA-A, -B, -C, -DRB1, and -DQB1 loci.
Patients typed using intermediate-resolution methods were retyped later
with high-resolution methods; this HLA typing was used to deﬁne the level
of mismatch.
Written informed consent for treatment was obtained from all patients
and donors. Approval for this retrospective review was obtained from the
center’s Institutional Review and Privacy Board.
Patients were followed according to standard clinical practice;
engraftment, acute and chronic GVHD, relapse, causes of death, and other
relevant transplant outcomes were captured in real time, and these data
were stored in an institutional database. This study was carried out using
these collected data and review of patients’ medical records.
Patients and disease characteristic are summarized in Table 1. The MDS
subtypes and prognostic classiﬁcation at diagnosis and before trans-
plantation were determined according to the World Health Organization
(WHO) [18] and the Revised International Prognostic Scoring (IPSS-R)
criteria [19]. Patients who responded to pre-cytoreduction treatment were
classiﬁed into 2 groups: those who achieved hematologic remission
and those who had a second refractory cytopenia phase. Complete
hematologic remission was deﬁned as cellular marrow with <5% blasts,
no overt dysplasia, and full recovery of blood counts with neutrophils >
1000/mL, platelets > 100,000/mL, RBC cell transfusion independent, and no
circulating blasts. Second refractory cytopenia was deﬁned as <5% blasts in
the bone marrow and no circulating blasts but persistent cytopenias
[20,21]. Evaluation of comorbidities and assignment of scores were
done using consistent deﬁnitions for coding the 17 components of the
hematopoietic cell transplantationespeciﬁc comorbidity index (HCT-CI)
[22].
Pretransplant Therapy
Ninety-nine patients were treated before admission for transplant to
induce remission or to decrease MDS tumor burden; 32 patients received
low-dose chemotherapy or hypomethylating agents, and 67 patients
received high-dose induction chemotherapy. Three patients did not receive
any induction therapy before starting preparative regimen.
Preparative Regimen
All patients were prepared for transplant with a myeloablative regimen,
15 with a hyperfractionated total body irradiation (TBI)ebased regimen and
87 with a chemotherapy-only regimen (Table 2) [15,16]. The use of a
chemotherapy-based preparative regimen started in 2000 and includedbusulfan, melphalan 140 mg/m2, and ﬂudarabine 125 mg/m2. Busulfan at
the dose of 8.0 mg/kg i.v. was given until October 2008; after that the dose
was increased to 9.6 mg/kg.
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steady-state level of 600 to 900 ng/mL, with the desired level closer to
900 ng/mL. All but 6 patients (5.9%) received antithymocyte globulin (ATG)
to prevent graft rejection. Eighty-seven patients (90.6%) received rabbit
ATG (2.5 to 5 mg/kg), and 9 patients (9.4%) received horse ATG (30 to
60 mg/kg).
Source of Hematopoietic Stem Cells
All patients received peripheral blood stem cells (PBSCs). Seventy-ﬁve
donors were HLA matched: 37 related and 38 unrelated. Twenty-seven
donors were mismatched: 25 unrelated and 2 related. With high-
resolution typing, the level of mismatch was 5/10 (n ¼ 2), 7/10 (n ¼ 1),
8/10 (n ¼ 5), and 9/10 (n ¼ 19).
CD34 Selection
CD34 selection of granulocyte colony-stimulating factoremobilized
PBSCs was accomplished by positive selection of CD34þ stem cells initially
using the ISOLEX 300i Magnetic Cell Separator (Baxter, Deerﬁeld, IL) and
subsequent sheep RBC rosette depletion (n ¼ 66) [16] and then since
October 2010 using the CliniMACS CD34 Reagent System [23] (Miltenyi
Biotech, Gladbach, Germany) (n ¼ 36). The TCD-PBSC allograft was infused
within 24 to 48 hours after completion of cytoreduction. No pharmacologic
post-transplant GVHD prophylaxis was given.
Unmanipulated donor lymphocyte and cytotoxic T lymphocyte infusions
Nine patients received donor leukocyte infusions and 3 cytotoxic T
lymphocytes (CTLs). Four patients received donor leukocyte infusions for
relapse and 3 for increasing mixed chimerism with no evidence of hema-
tologic relapse. Two patients received donor leukocyte infusions as treat-
ment for an opportunistic infection. Cytomegalovirus CTLs were given to
1 patient, Epstein-Barr virus CTLs to 1 patient, and dual speciﬁc cytomega-
lovirus and Epstein-Barr virus cells were given to another patient.
Supportive Care
All patients received supportive care and prophylaxis against opportu-
nistic infections according to standard guidelines. Patients conditioned with
busulfan received seizure prophylaxis with phenytoin or levetiracetam
(since 2008). Granulocyte colony-stimulating factor was given beginning on
day þ 7 post-transplant.
Outcome Deﬁnitions
Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive days
with an absolute neutrophil count  500/mL. Engraftment was conﬁrmed
by documentation of chimerism in the bone marrow cells using karyotype
or ﬂuorescent in situ hybridization of the X and Y chromosomes in
sex-mismatched donorerecipient pairs and by measurement of DNA re-
striction fragment length polymorphisms or short tandem repeats in sex-
matched pairs.
Primary graft failure was deﬁned as the absence of neutrophil recovery
(500/mL) by day 28 and bone marrow biopsy  5% cellularity. Secondary
graft failure was deﬁned as loss of absolute neutrophil count < 500/mL after
primary engraftment, with bone marrow biopsy showing less than 5%
cellularity.
Acute and chronic GVHD were evaluated according to the Center for
International Blood and Marrow Transplant Research (CIBMTR) [11] and the
National Institutes of Health (NIH) [12] criteria in patients who
survived 21 and 100 days with engraftment, respectively. Because these
criteria are relatively recent, particularly the NIH criteria, acute and chronic
GVHD in patients transplanted before these criteria, were graded according
to the Keystone criteria [24] for acute GVHD and Sullivan et al. criteria [25]
for chronic GVHD. Staging and characteristics on GVHD were collected in
real time, and the ﬁnal grading was established by a GVHD Consensus
Committee. Conversion of GVHD grading according to current criteria was
made by the main investigators of this article and validated by the GVHD
Consensus Committee and was based on review of previously captured
GVHD data and chart review.
Hematologic relapse was deﬁned as recurrence of cytopenias associ-
ated with marrow morphologic changes diagnostic of MDS. Cytogenetic
relapse was deﬁned as recurrence of pretransplantation chromosome
abnormalities.
Relapse-free survival (RFS) was deﬁned as being alive and without ev-
idence of relapse (as above). Chronic GVHD/RFS (CRFS) is a composite
outcome and we used the Blood and Marrow Transplant Clinical Trials
Network (BMT CTN) deﬁnition that is used for the GVHD prophylaxis trial
(BMT CTN 1301). The time to event outcomes are deﬁned as moderate to
severe chronic GVHD by the NIH consensus criteria, disease relapse, or death
by any cause. Causes of death were deﬁned according to the National
Marrow Donor Program’s algorithm [26].Statistical Methods
Estimates of overall survival (OS), RFS, and CRFS were calculated using
the Kaplan-Meier method [27], with survival distributions compared across
patient or treatment characteristics using the log-rank test statistic. Relapse
or death were considered events for RFS, whereas chronic GVHD, relapse, or
death were considered events for CRFS. Cumulative incidence estimates of
acute and chronic GVHD, relapse, and nonrelapse mortality (NRM) were
based on the cumulative incidence method for competing risks. Relapse,
death in the absence of relapse, and relapse or death in the absence of GVHD
were considered competing risks for NRM, relapse, and GVHD, respectively.
Evaluation of differences in these outcomes based on day 100 CD4 counts
was performed via a landmark analysis. Gray’s test was used to compare the
incidence of relapse, NRM, and GVHD across groups [28]. The Cox propor-
tional hazards model was used to investigate the cause-speciﬁc hazard of
relapse in adjusted multivariate models. All tests were 2-sided and
considered signiﬁcant at the .05 level. Statistical analyses were completed
using R version 3.1.2 (http://www.r-project.org/).
RESULTS
Disease Status before Conditioning
Of the 102 patients, 99 were treated before the start of
cytoreduction to induce remission or to reduce the blast
count. Disease status at the time of diagnosis and at trans-
plant is summarized in Table 1. Disease had progressed
before transplant in 66 patients. In 27 patients with re-
fractory anemia/refractory cytopenia with multilineage
dysplasia (RA/RCMD), their disease progressed to RAEB-1 in
8, to RAEB-2 in 6, and to AML in 13. In 20 patients with RAEB-
1, their disease progressed to RAEB-2 in 5 patients and to
AML in 15. In 19 patients with RAEB-2, their disease pro-
gressed to AML. Most patients (83%) were in complete
remission or in a second cytopenic phase before condition-
ing. Themedian time from diagnosis to transplant in patients
who were diagnosed with RA/RCMD was 34.3 months
(range, 4.7 to 161.1), in patients with RAEB-1 6.5 months
(range, 1.8 to 43.6), and in patients with RAEB-2 8.2 months
(range, 2.3 to 28.6).
Engraftment
Median cell dosewas 7.2106 CD34/kg (range, .6 to 28.8).
Three patients died before day 28 andwere not assessalbe for
engraftment. The median time to neutrophil engraftment
was 11 days (range, 8 to 21). Graft rejection occurred in 1
patientwho underwent a second unmodiﬁed transplant from
the original donor and died on day 107 from ﬁrst transplant.
Acute and Chronic GVHD
Ninety-nine patients were assessable for GVHD. Cumula-
tive incidences of grades II to IV acute GVHDwere 9.8% at day
100 (95% conﬁdence interval [CI], 5.0% to 16.5%) and 15.7% at
6months (95% CI, 9.4% to 23.4%) (Figure 1). Six patients (6.8%)
developed grade I skin only that resolved with topical ste-
roids and 13 patients (13.1%) required systemic immuno-
suppressive treatment. Factors found to be associated with
aGVHDwere recipient male gender (P¼ .021) and donor type
(P ¼ .023). Cumulative incidences of grades II to IV acute
GVHD at 6 months were 5.4% (95% CI, .9% to 16.1%) in re-
cipients of a matched related donor grafts, 21.1% (95% CI, 9.7%
to 35.2%) in recipients of a matched unrelated donor grafts,
and 22.2% (95% CI, 8.8% to 39.4%) in recipients of a mis-
matched donor grafts. Chronic GVHD developed only in 4
patients with a cumulative incidence at 1 year of 3.9% (95% CI,
1.3% to 9.0%). Three patients hadmild and 1 patient moderate
chronic GVHD that required systemic immunosuppression.
Relapse
Disease relapsed in 19 patients with cumulative in-
cidences of 11.8% at 1 year (95% CI, 6.4% to 18.9%) and 15.7%
Figure 1. Cumulative incidence of acute and chronic GVHD.
Figure 2. The cumulative incidence of relapse for the whole group of patients
is shown (red line). Relapse was signiﬁcantly higher for patients with poor and
very poor cytogenetic abnormalities according to IPSS-R categories (purple
line) (P ¼ .01). (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
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(63%) occurred within the ﬁrst year post-transplant; 2 pa-
tients relapsed before day 100 with the earliest relapse on
day 46 post-transplant. Of 19 relapsed patients only 3
are alive.
High-risk cytogenetic abnormalities according to IPSS-R
at time of diagnosis and pretransplant therapy with hypo-
methylating agents were associated with higher relapse
incidence (Table 3). In patients with poor-risk and very-poor-
risk cytogenetic abnormalities at diagnosis, cumulative in-
cidences of relapse post-transplant were 25.0% at 1 year (95%
CI, 11.5% to 41.1%) and 31.2% at 2 years (95% CI, 16.0% to 47.8%)
(Figure 2). The cumulative incidence of relapse at 1 year was
signiﬁcantly lower in patients with good (4.3%; 95% CI, .8% toTable 3
Correlation of Relapse and NRM with Patient, Disease, and Transplant Characterist
Relapse (%)
1 Year 2 Year P
Overall 11.8 (6.4-18.9) 15.7 (9.4-23.4) d
Age, yr .38
50 11.5 (2.8-27.1) 23.1 (9.1-40.8)
50-65 12.7 (5.9-22.2) 14.3 (7.0-24.1)
>65 7.7 (.4-30.6) 7.7 (.4-30.6)
Etiology .84
Primary/secondary 10.3 (5.1-17.8) 14.9 (8.4-23.3)
Therapy related 20.0 (4.4-43.5) 20.0 (4.4-43.5)
Cytogenetic risk at diagnosis .01
Very good/good 4.3 (.8-13.0) 4.3 (.8-13.0)
Intermediate 5.3 (.3-22.0) 15.8 (3.7-35.6)
Poor/very poor 25.0 (11.5-41.1) 31.2 (16.0-47.8)
Pretransplant therapy .03
Chemotherapy 9.0 (3.6-17.3) 10.5 (4.5-19.2)
Hypomethylating agents 18.8 (7.5-34.0) 28.1 (13.8-44.4)
Conditioning regimen .35
Chemotherapy 10.3 (5.1-17.8) 13.8 (7.5-22.0)
TBI 20.0 (4.5-43.5) 26.7 (7.6-50.8)
Match type .60
Match-related 10.8 (3.4-23.3) 16.2 (6.4-29.9)
Match-unrelated 13.2 (4.7-26.0) 13.2 (4.7-26.0)
Mismatch 11.1 (2.7-26.3) 18.5 (6.5-35.3)
HCT-CI .84
0 5.6 (.3-23.1) 11.1 (1.7-30.5)
1-2 11.5 (2.8-27.2) 15.4 (4.6-31.9)
 3 14.0 (6.5-24.4) 17.5 (8.9-28.5)
CD 34 selection method .79
Clinimacs 8.3 (2.1-20.3) 13.9 (5.0-27.3)
Isolex 13.6 (6.7-23.1) 16.7 (8.8-26.7)
Values in parentheses are 95% CIs.13.0%) and intermediate (5.3%; 95% CI, .3% to 22.0%) risk cy-
togenetic abnormalities (P ¼ .011).
To determine the effect of cytogenetic remission on
relapse, 28 patients in the poor- and very-poor-risk cytoge-
netic categories were divided into 2 groups according to the
level of cytogenetic remission before conditioning: 16 ach-
ieved hematologic and cytogenetic remission and 12 were in
hematologic remission but had persistent cytogenetic ab-
normalities. The cumulative incidence of relapse at 1 year
was 25.0% in both groups. The 1-year cumulative incidence of
relapse among patients treated with hypomethylating
agents/low-dose chemotherapy was 18.8% (95% CI, 7.5% toics
NRM (%)
Day 100 1 Year 5 Year P
7.8 (3.7-14.1) 22.5 (15.0-31.1) 33.4 (24.2-42.6) d
9 .230
.00 (NA) 15.4 (4.7-31.9) 26.9 (11.6-45.0)
7.9 (2.9-16.3) 20.6 (11.6-31.4) 31.8 (20.7-43.5)
23.1 (5.1-48.5) 46.2 (17.7-70.8) 53.8 (22.8-77.2)
3 .222
6.9 (2.8-13.5) 21.8 (13.8-31.1) 32.3 (22.7-42.2)
13.3 (2.0-35.4) 26.7 (7.7-50.6) 40.0 (15.4-63.9)
1 .338
12.8 (5.1-24.0) 23.4 (12.5-36.3) 34.0 (20.9-47.7)
.00 (NA) 5.3 (.3-22.1) 21.1 (6.2-41.8)
6.3 (11-18.4) 28.1 (13.8-44.4) 37.5 (20.8-54.1)
1 .071
9.0 (3.6-17.3) 28.4 (18.1-39.5) 38.9 (27.2-50.5)
6.3 (11-18.4) 9.4 (2.3-22.5) 21.9 (9.4-37.6)
2 .841
9.2 (4.3-16.4) 21.8 (13.8-31.1) 33.3 (23.7-43.4)
.00 (NA) 26.7 (7.7-50.6) 33.3 (11.3-57.5)
7 .807
5.4 (.9-16.1) 21.6 (10.0-36.1) 32.6 (18.0-48.0)
13.2 (4.7-26.0) 23.7 (11.6-38.2) 31.6 (17.5-46.7)
3.7 (.03-16.2) 22.2 (8.8-39.4) 37.0 (19.2-55.0)
5 .382
.00 (NA) 16.7 (3.9-37.2) 22.2 (6.6-43.6)
7.7 (13-22.1) 23.1 (9.1-40.7) 30.8 (14.3-49.0)
10.5 (4.2-20.1) 22.8 (12.9-344) 36.8 (24.4-49.3)
7 .664
8.3 (2.1-20.3) 22.2 (10.3-37.0) 30.6 (16.4-46.0)
7.6 (2.8-15.6) 22.7 (13.5-33.5) 34.8 (23.5-46.4)
Table 4
Correlation of OS and RFS with Patient, Disease, and Transplant Characteristics
OS (%) RFS (%)
2 Year 5 Year P 2 Year 5 Year P
Overall 56.9 (48.0-67.3) 49.3 (40.4-60.2) d 52.0 (41.9-61.1) 47.6 (37.5-56.9)
Age, yr .07 .127
50 57.7 (36.8-73.9) 49.1 (28.8-66.6) 50.0 (29.9-67.2) 45.0 (25.2-63.0)
50-65 60.3 (47.2-71.2) 55.4 (42.3-66.7) 55.6 (42.5-66.8) 53.9 (40.9-65.3)
>65 38.5 (14.1-62.8) 15.4 (1.2-45.3) 38.5 (14.1-62.8) 20.5 (3.9-46.3)
Etiology .109 .140
Primary/secondary 59.8 (48.7-69.2) 50.8 (39.7-60.9) 54.0 (43.0-63.8) 48.8 (37.8-58.9)
Therapy related 40.0 (16.5-62.8) 40.0 (16.5-62.8) 40.0 (16.5-62.8) 40.0 (16.5-62.8)
Cytogenetic risk at diagnosis .002 <.001
Very good/good 63.8 (51.5-79.2) 55.9 (43.0-72.8) 61.7 (49.3-77.3) 56.6 (43.8-73.1)
Intermediate 73.7 (56.3-96.4) 63.2 (44.8-89.0) 68.4 (50.4-92.9) 63.2 (44.8-89.0)
Poor/very poor 40.6 (26.7-61.8) 34.4 (21.3-55.5) 31.2 (18.7-52.2) 27.8 (15.8-48.8)
Cytogenetic risk at transplant .220 .162
Very good/good 59.7 (49.7-71.8) 52.6 (42.4-65.2) 55.8 (45.8-68.1) 50.1 (40.0-62.8)
Intermediate 41.7 (21.3-81.4) 41.7 (21.3-81.4) 41.7 (21.3-81.4) 41.7 (21.3-81.4)
Poor/very poor 53.8 (32.6-89.1) 38.5 (19.3-76.5) 38.5 (19.3-76.5) 38.5 (19.3-76.5)
Pretransplant therapy .619 .856
Chemotherapy 53.7 (43.0-67.1) 48.7 (38.0-62.5) 52.2 (41.5-65.7) 47.4 (36.8-61.1)
Hypomethylating agents 62.5 (47.8-81.7) 49.2 (34.3-70.4) 50.5 (35.4-70.7) 45.0 (30.1-67.4)
Conditioning regimen .847 .516
Chemotherapy 58.6 (49.1-69.9) 49.8 (40.2-61.7) 54.0 (44.5-65.6) 48.9 (39.3-60.7)
TBI 46.7 (27.2-80.2) 46.7 (27.2-80.2) 40.0 (21.5-74.3) 40.0 (21.5-74.3)
Match type .602 .506
Match-related 59.5 (45.6-77.6) 53.9 (40.0-72.7) 54.1 (40.2-72.8) 51.2 (37.4-70.2)
Match-unrelated 57.9 (44.1-75.9) 52.1 (38.3-70.9) 55.3 (41.5-73.6) 52.4 (386-71.0)
Mismatch 51.9 (36.1-74.6) 39.5 (24.4-63.9) 44.4 (29.2-67.8) 35.9 (21.4-60.2)
HCT-CI .140 .253
0 66.7 (48.1-92.4) 66.7 (48.1-92.4) 66.7 (48.1-92.4) 60.0 (40.8-88.3)
1-2 61.5 (45.4-83.4) 57.4 (41.2-80.1) 53.8 (37.7-76.9) 53.8 (37.7-76.9)
3 52.6 (41.1-67.3) 41.7 (30.6-56.9) 47.4 (36.0-62.3) 42.0 (31.0-57.0)
CD34 selection method
Clinimacs 58.3 (44.3-76.9) 55.3 (41.1-74.3) .538 55.6 (41.5-74.4) 50.5 (35.7-71.4) .520
Isolex 56.1 (45.3-69.4) 47.0 (36.3-60.7) 50.0 (39.3-63.6) 45.5 (34.9-59.2)
Values in parentheses are 95% CIs.
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treated with induction chemotherapy (P ¼ .031). In a multi-
variate model adjusted for both cytogenetic risk at diagnosis
and pretransplant therapy, cytogenetic risk at diagnosisTable 5
Causes of Death
Cause Value
Relapse 17 (31.5%)
Infections 18 (33.3%)
Bacterial 8
Viral 8
Fungal 1
Other (PCP) 1
GVHD 5 (9.3%)
Other 7 (13.0%)
Recurrence of primary malignancy 2 (MCL, neuroblastoma)
Secondary malignancy 1 (lung cancer)
Portal HTN and GI bleed 1
Acute hemolytic anemia 1
Postsurgical death 1
Pericarditis 1
Toxicity 4 (7.4%)
VOD 1
Lung 3
Graft failure 2 (3.7%)
Graft rejection 1
Late graft failure 1
Organ failure 1 (1.9%)
Respiratory failure 1
Total 54
PCP indicates; pneumocystis carinii; MCL, mantle cell lymphoma; HTN,
hypertension; GI, gastrointestinal; VOD, veno-occlusive disease.remained a signiﬁcant predictor of relapse (P ¼ .003). Inter-
mediate (hazard ratio, 1.45; 95% CI, .32 to 6.49) or poor/very
poor (hazard ratio, 6.09; 95% CI, 1.91 to 19.43) cytogenetic
risk at diagnosis was associated with greater risk of relapse,
as compared with good cytogenetic risk at diagnosis.
Survival
At time of analysis, 48 patients were alive at a median of
6.0 years post-transplant (range, 2.0 months to 12.6 years).
Rates of OS and RFS at 2 years post-transplant were 56.9%
(95% CI, 48.0% to 67.3%) and 52.0% (95% CI, 41.9% to 61.1%),
respectively, and at 5 years 49.3% (95% CI, 40.4% to 60.2%) and
47.6% (95% CI, 37.5% to 56.9%), respectively (Figure 3). The
only factor found to be associatedwith worse OS and RFSwas
high-risk cytogenetic abnormalities at time of diagnosis
(Table 4). Older age (>65) was also associated with worse OS
rates: 38.5% (95% CI, 14.1% to 62.8%) at 2 years and 15.4% (95%
CI, 1.2% to 45.3%) at 5 years (P ¼ .074); however, age did not
affect RFS (P ¼ .127). There was a trend for lower rates of OS
and RFS in patients with a high comorbidity score, but these
differences did not reach statistical signiﬁcance (P ¼ .140 and
.253, respectively). Rates of CRFS in this cohort of patients
overlapped with that of RFS, at 51.0% (95% CI, 40.9% to 60.2%)
at 2 years and 46.6% (95% CI, 36.6% to 56.0%) at 5 years post-
transplant, reﬂecting the very low incidence of chronic
GVHD.
NRM and Causes of Death
Fifty-four patients (52.9%) died by the time of this anal-
ysis; 17 (31.5%) due to relapse and 37 (68.5%) due to
Figure 3. OS (overall survival), RFS (relapse free survival), and the composite
end-point of chronic GVHD and relapse free survival (CRFS) are overlapping,
indicating that patients who after transplant and free of disease are also free of
chronic GVHD.
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deaths in this series were infections (33.3%), followed by
GVHD (9.2%) and organ toxicity (7.4%). Among the 5 patients
in whom the cause of death was attributed to GVHD, 3 had
active infection at the time of death. Among the infectious
causes, the most commonwere bacterial and viral infections.
Cumulative incidences of NRM post-transplant were 7.8%
at day 100 (95% CI, 3.7% to 14.1%) and 22.5% at 1 year (95% CI,
15.0% to 31.1%) (Figure 4). Rate of NRM at 1 year for patients
whose CD4 count was less than 100/mL at day 100 post-
transplant was higher compared with patients whose CD4
count was higher (20.6% versus 11.4%, P¼ .070). Patients who
received induction chemotherapy before transplant had
higher rates of NRM (9.0% by day 100 and 28.4% by 1 year) in
comparison with patients who received hypomethylating
agents or low-dose chemotherapy pretransplant (6.3% by day
100 and 9.4% by 1 year, P ¼ .071).DISCUSSION
We demonstrate in this large cohort of patients with
advanced MDS that ex vivo TCD-HSCT by positive CD34
selection produce an OS and a RFS that are comparable with
that reported after unmodiﬁed transplants [29-32], with aFigure 4. Cumulative incidence of NRM.much lower incidence of acute GVHD and negligible inci-
dence of cGVHD and without a high relapse rate. The
method of TCD used in this series of advanced MDS patients
has been extensively used by us and others, and the efﬁcacy
of this method in preventing acute and chronic GVHD has
been well documented in AML [14,33], acute lymphoblastic
leukemia [34], chronic myeloid leukemia [14], and non-
Hodgkin leukemia [16] as well as a small series of patients
with advanced MDS [15]. More recently, a multicenter
prospective phase II trial in patients with AML in remission
sponsored by the BMT CTN conﬁrmed our ﬁndings [13].
Moreover, comparison of our TCD experience with un-
modiﬁed transplants in MDS after either myeloablative
conditioning (MAC) or reduced-intensity conditioning (RIC)
shows that CD34-selected allo-HSCT signiﬁcantly lowers
acute and chronic GVHD.
The early experience with unmodiﬁed transplants for
MDS has been mostly with MAC, and this was associated
with a high incidence of acute GVHD and a high incidence of
NRM related to the toxicities of the preparative regimens
[31]. The use of RIC in MDS patients has decreased toxicities
and NRM as well as the incidence of acute GVHD without
changing the incidence of chronic GVHD; however, RIC is
associated with a higher incidence of relapse. The overall
effect of these different complications has resulted in similar
OS and RFS in MAC and RIC transplants for MDS patients,
with a signiﬁcant proportion of them suffering from GVHD
[31]. Although the composite outcome CRFSda parameter
that measures freedom from ongoing morbidity and repre-
sents ideal HCT recoverydhas not been reported in previous
studies of allo-HSCT in MDS, a recent study [35] including
MDS patients and other hematologic malignancies reported
a 20% difference in RFS and CRFS at 1 year post-transplant.
This difference was due to moderate to severe acute and
chronic GVHD. We show in this series that the CRFS is almost
identical to RFS given that the incidence of moderate to
severe chronic GVHD is quite low (<1%).
The advantages and disadvantages of TCD transplant in
comparison with unmodiﬁed transplants have not been
properly assessed in a randomized trial including exclusively
high-risk MDS patients. The National Marrow Donor Pro-
gram trial comparing unmodiﬁed to TCD transplants in a
variety of hematologic diseases showed no differences in OS
and RFS, although the incidence of GVHD was signiﬁcantly
lower in recipients of TCD transplants [36]. The main limi-
tation of this trial was that T cell depletionwas performed by
more than 1 method and resulted in different levels of T cells
depletion. A CIBMTR study compared retrospectively the
outcomes of 44 patients who participated in the CTN spon-
sored phase II trial of TCD by CD34 selection with the Mil-
tenyi device [13] with those of 84 recipients of unmodiﬁed
transplants requiring post-transplant immunosuppression
transplanted during the same time period [37]. There were
no differences in rates of graft rejection, leukemia relapse,
treatment-related mortality, RFS, and OS. However, at 1 year,
54% and 12% of patients were still on immunosuppression
in the immune suppression therapy and TCD cohorts,
respectively. T cell depletion was associated with a higher
GVHD-free survival at 2 years compared with immune sup-
pression therapy (41% versus 19%, respectively; P ¼ .006).
A large randomized trial is now undergoing to determine the
optimal GVHD prevention strategy in the context of MAC.
This trial, performed under the auspices of the National
Heart, Lung and Blood Institute and the National Cancer
Institute, will compare CD34 selection to post-transplant
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trexate, with a primary endpoint of CRFS.
Our method of ex vivo TCD also produces equivalent
or better outcomes when compared with in vivo TCD
with alemtuzumab. Potter et al. [38] recently published their
experience with an alemtuzumab-based RIC regimen in pa-
tients with MDS and AML evolved from MDS. Rates of OS,
RFS, NRM, relapse, and chronic GVHD at 5 years post-
transplant were 44%, 33%, 26%, 51%, and 19%, respectively.
The incidence of chronic GVHD was higher in the
alemtuzumab-treated patients, 19% versus 4% in our series,
likely due to the depth of TCD. The ex vivo method used at
our institution produce a 3 to 4 log depletion compared with
a 2 log depletion caused by alemtuzumab. Also, despite the
use of RIC, the rate of NRM at 1-year post-transplant in the
alemtuzumab series was 20%, similar to the 24% in our cohort
of patients who received a MAC regimen. One signiﬁcant
difference comparing these 2 series is the higher relapse rate
in the alemtuzumab group, 40% at 2 years post-transplant
despite the fact that most patients were transplanted
without excess blasts, versus 19.8% in our cohort. The lower
relapse rate in our cohort of patients is likely attributed to the
higher intensity preparative regimen.
Another emerging method of in vivo TCD is with post-
transplant high-dose cyclophosphamide. The outcomes of
this approach in patients with hematologic malignancies
were assessed in a multi-institutional prospective study re-
ported by Kanakry et al. [39], where all patients receivedMAC
followed by high-dose post-transplant cyclophosphamide as
the sole GVHD prophylaxis. Donors were matched related or
unrelated, and graft source was bone marrow. Although
grades II to IV acute GVHDwas as high as 51% by day 100 post-
transplant, grades III to IVwasonly15%andchronicGVHDwas
as low as 14%. NRM rates were 9% at day 100 post-transplant
and 16% at 1-year post transplant, with a relapse rate of 22%
at 2 years post-transplant. One of the potential advantages of
this approach is that cyclophosphamide does not deplete
memory T cells, and patients are not severely immunodeﬁ-
cient and may have a lower rate of infectious complications.
The CTN trial described before will hopefully determine
whether thismethod canproduce the sameoutcomesasCD34
selection and pharmacologic GVHD prophylaxis.
An intensive conditioning is required before TCD trans-
plant to provide a more intense antileukemic effect because
the graft-versus-MDS effect [32,40,41] might be reduced and
also to induce a more profound immunosuppression and
thereby to decrease the risk of graft rejection. A high-dose
TBI-based conditioning regimen was used more frequently
in the early days; however, most patients (86%) received
a chemotherapy-only preparative regimen. We did not
observe difference in outcomes comparing full-dose TBI-
based regimens and chemotherapy-only based regimens;
however, the TBI group included only 2 patients older than
60 and no patients older than 65 compared with 35 patients
older than 60 and 17 older than 65 in the chemotherapy-
based conditioning regimen. The chemotherapy-only MAC
regimen combining busulfan, melphalan, ﬂudarabine, and
rabbit ATG was well tolerated, with an overall rate of NRM at
day 100 of 7.8% (95% CI, 3.7% to 14.1%). Higher NRM rates,
23.1% (95% CI, 5.1% to 48.5%), were seen in patients older than
65 who also had a higher HCT-CI (85% with HCT-CI > 3).
Although there was no statistically signiﬁcant differences in
NRM between the different age groups (P ¼ .230), intuitively
older patients are expected to tolerate less well the mye-
loablative preparative regimen necessary for TCD transplant.With the growth of the elderly population, patients in their
seventh and eighth decades of life are now candidates for
allo-HSCT, and that underscores the importance of devel-
oping less-toxic preparative regimens to beneﬁt particularly
older patients.
The relapse rate in this series disproves the belief that
recipients of TCD transplants have higher relapse rates as
compared with unmodiﬁed transplants. The Fred Hutch-
inson Cancer Center reported cumulative incidences of
relapse at 2 years ranging between 16% for patients with low-
risk disease by the IPSS-R cytogenetic risk group to 35% for
patients with high-risk disease [29,42], which is similar to
our outcomes. Similarly, a CIBMTR study showed relapse
rates in the order of 25% to 28% and higher in patients with
poor-risk cytogenetic abnormalities or patient who under-
went non-MAC regimens [43]. Relapse strongly correlated in
our series with cytogenetic risk at diagnosis, similarly to
what has been published for patients undergoing unmodi-
ﬁed transplant in a large retrospective study reported by the
European Group for Blood and Marrow Transplantation [44].
Patients with poor-risk cytogenetic abnormalities had a
relapse rate of 31% at 1 year compared with only 17% in
patients with intermediate risk and 8% in patients with
low risk. The poor outcomes of patients who relapse after
allo-HSCT [45-47], irrespective of the type of transplant,
emphasize the need for better strategies such as molecular
mutations to identify patients who are at higher risk for
relapse for whom post-transplant prophylaxis against
relapse should be offered. One of these approaches is adop-
tive immune therapy with unmanipulated or leukemia
antigenespeciﬁc cytotoxic lymphocytes. A great advantage
of TCD transplants is that the probability of GVHD is low, and
therefore adoptive immune therapy is more feasible.
Administration of chemotherapy to patients with
advanced MDS before conditioning has been a matter of
debate over the years [10,48-50]. Based on our previous
published experience [15], most patients underwent treat-
ment before initiation of cytoreduction therapy and had less
than 10% blasts at time of admission for transplant. The re-
sults of this study conﬁrm our earlier observations that
achieving hematologic remission or a minimal residual dis-
ease state before TCD transplant signiﬁcantly reduces the
risk of post-transplant relapse. In contrast to the importance
of reduction of blasts and achieving morphologic remission
before transplant, we could not demonstrate in this series
that achieving cytogenetic remission before transplant re-
duces relapse risk. Induction chemotherapy and hypo-
methylating agents are the 2 main options to reduce disease
burden before transplant, and there are pros and cons to each
option [51]. Damaj et al. [52] studied the outcome of 163
patients with MDS who were treated pretransplant by either
azacitidine, induction chemotherapy, or azacitidine preceded
or followed by induction chemotherapy and reported no
difference in OS, RFS, relapse, and NRM when comparing
azacitidine to induction chemotherapy. However, patients
who received both azacitidine and induction chemotherapy
hadworse outcomes, particularly high risk of NRM and lower
OS and RFS. In our cohort there was no difference in OS and
RFS among patients who were treated with either induction
chemotherapy or azacitidine; however, there was a higher
relapse incidence in the azacitidine group and a trend toward
lower NRM. Prospective studies are needed to deﬁne the best
treatment to achieve remission before transplant.
NRM was the main cause of failure in this series of pa-
tients, and this abrogated the beneﬁts of reduced GVHD.
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counting for 33% of causes of death. The basis for this has
been established; the TCD methods used in these patients
causes profound depletion of immunocompetent T cells, and
as a result patients are severely immunodeﬁcient [53].
Moreover, the process of immune reconstitution is extremely
slow [54], particularly in older patients who have poor
thymic function [55]. This was conﬁrmed in this cohort,
in which the median CD4 counts at 3 and 6 months
post-transplant were 116 cells/mL (range, 0 to 1233) and
136 cells/mL (range, 0 to 722) respectively.
In summary, the outcomes of patients with advanced
MDS transplanted with TCD allografts are favorable and are
similar to those reported for patients who underwent un-
modiﬁed transplant with the advantage of much lower
incidence of acute and chronic GVHD. Delayed immune re-
covery and infections remainmain obstacles to the success of
TCD allo-HSCT. However, freedom from GVHD and no need
for the use of immunosuppressive medications can be used
as a platform for early post-transplant intervention in the
form of speciﬁc cytotoxic CTLs to treat mostly viral infections
and to enhance the graft-versus-leukemia effect without
paying the price of GVHD.ACKNOWLEDGMENTS
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